Publications by authors named "D Bechard"

Claim this Profile
N
Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v.
Hana Matuskova, Pavel Marasek, Vladyslav Mazhara, Ekaterina Simonova, Lucie Kosinova

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.
Stephane Champiat, Elena Garralda, Vladimir Galvao, Philippe A Cassier, Carlos Gomez-Roca, David Bechard

Cell Rep Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
Zuzana Antosova, Nada Podzimkova, Jakub Tomala, Katerina Augustynkova, Katerina Sajnerova, David Bechard

Front Immunol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pandemic Dreams: Network Analysis of Dream Content During the COVID-19 Lockdown.
Anu-Katriina Pesonen, Jari Lipsanen, Risto Halonen, Marko Elovainio, Nils Sandman

Front Psychol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Mélanie Desbois, Coralie Béal, Mélinda Charrier, Benjamin Besse, Guillaume Meurice

J Immunother Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis